Huakang Biomedical Holdings Company Limited provided group earnings guidance for the year ended 31 December 2023. Based on the information currently available to the board of directors of the Company, including the preliminary review of the latest unaudited consolidated management accounts of the Group, the Board informed the shareholders of the Company and potential investors that the Group is expected to record a loss attributable to owners of the Company of not more than RMB 5.8 million for the year ended 31 December 2023 (the "Current Year") as compared with approximately RMB 3.1 million for the year ended 31 December 2022 (the "Corresponding Year").
Huakang Biomedical Holdings Company Limited
Equities
8622
KYG4644W1069
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.098 HKD | -5.77% | -1.01% | -8.41% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-8.41% | 6.27M | |
-0.60% | 12.63B | |
-9.59% | 7.67B | |
+1.82% | 5.42B | |
+0.02% | 4.57B | |
-47.68% | 3.51B | |
+6.42% | 2.59B | |
-14.59% | 2.05B | |
-8.29% | 1.79B | |
+2.25% | 1.77B |
- Stock Market
- Equities
- 8622 Stock
- News Huakang Biomedical Holdings Company Limited
- Huakang Biomedical Holdings Company Limited Provides Group Earnings Guidance for the Year Ended 31 December 2023